NEW YORK (GenomeWeb News) – Newfound Genomics, a genetic research and genotyping services firm based in St. Johns, Newfoundland, today said that it has signed a memorandum of understanding with the Genesis Group that provides Newfound with the opportunity to commercialize certain discoveries from Memorial University in the field of human genetics.
Genesis Group is the commercialization arm of the university, where Newfound CEO Wayne Gulliver is a professor of medicine and dermatology. The tech transfer group also inked a second pact with Newfound that provides the firm with certain exclusive rights to develop and market a test for arrhythmogenic right ventricular cardiomyopathy.
Concurrent with that pact, Newfound granted an exclusive sub-license to Clinical Data’s PGxHealth unit to perform and market a test to diagnose AVRC in the US, Europe, and certain other undisclosed territories.
Gulliver said that Newfound “will be making this test available in a matter of weeks.”